Athira Pharma, Inc. (NASDAQ:LONA) Stock Has Consensus Target Price of $17.33 According to Analysts

Posted by George Bondi on Oct 6th, 2026

Athira Pharma, Inc. (NASDAQ:LONA – Get Free Report) has earned a consensus rating of “Moderate Buy” from the six analysts that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. The average 1 year target price among brokers that have covered the stock in the last year is $17.33.

Several brokerages recently weighed in on LONA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Athira Pharma in a research report on Friday, August 7th. Mizuho reduced their target price on Athira Pharma from $16.00 to $15.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 19th. Finally, Citizens Jmp decreased their price target on Athira Pharma from $18.00 to $17.00 and set a “market outperform” rating on the stock in a research note on Monday, August 17th.

Check Out Our Latest Stock Analysis on LONA

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Seven Fleet Capital Management LP acquired a new position in shares of Athira Pharma in the 4th quarter worth approximately $969,000. Spruce Street Capital LP purchased a new stake in Athira Pharma in the fourth quarter valued at approximately $2,980,000. Finally, Commodore Capital LP purchased a new stake in Athira Pharma in the fourth quarter valued at approximately $3,515,000. Hedge funds and other institutional investors own 57.12% of the company’s stock.

Athira Pharma Price Performance

NASDAQ:LONA opened at $5.58 on Tuesday. The company’s 50-day moving average is $6.91 and its two-hundred day moving average is $8.36. Athira Pharma has a 1-year low of $2.21 and a 1-year high of $14.21. The firm has a market capitalization of $52.40 million, a price-to-earnings ratio of -1.33 and a beta of 2.11.

Athira Pharma (NASDAQ:LONA – Get Free Report) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.20). As a group, equities analysts anticipate that Athira Pharma will post -2.67 earnings per share for the current fiscal year.

About Athira Pharma

(Get Free Report)

Athira Pharma, Inc is a clinical-stage biotechnology company focused on developing regenerative medicines for neurodegenerative diseases and other conditions involving impaired neuronal function. The company’s research has centered on the hepatocyte growth factor (HGF) biological pathway, which is associated with neuronal health, repair and regeneration.

Athira’s lead investigational product was fosgonimeton, also known as ATH-1017, an injectable therapy designed to activate the HGF/MET pathway.